Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
03/2000
03/15/2000EP0984968A1 Salts of aromatic sulphonic acids
03/15/2000EP0984966A1 9-AZABICYCLO(3.3.1)NON-2-ENE AND NONANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACh RECEPTORS
03/15/2000EP0984965A1 8-azabicyclo(3,2,1)oct-2-ene and octane derivatives as cholinergic ligands at nicotinic ach receptors
03/15/2000EP0984961A1 Novel pyridine derivatives and pharmaceutical compositions containing them
03/15/2000EP0984960A1 N-triazolyl-2-indolecarboxamides and their use as cck-a agonists
03/15/2000EP0984959A1 Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
03/15/2000EP0984956A1 Indoline derivatives as 5ht2c receptor antagonists
03/15/2000EP0984955A1 SUBSTITUTED 2-(2,6-DIOXOPIPERIDIN-3-YL)-PHTHALIMIDES AND 1-OXOISOINDOLINES AND METHOD OF REDUCING TNF$g(a) LEVELS
03/15/2000EP0984954A1 Anti-mitotic agents which inhibit tubulin polymerization
03/15/2000EP0984952A1 A new salt
03/15/2000EP0984943A1 Azacyclooctane and heptane derivatives, their preparation and usein therapy
03/15/2000EP0984940A1 Cyanoamidines as cell proliferation inhibitors
03/15/2000EP0984939A1 Cyanoguanidines as cell proliferation inhibitors
03/15/2000EP0984938A1 Cyanoguanidines as cell proliferation inhibitors
03/15/2000EP0984937A1 Cyanoguanidines as cell proliferation inhibitors
03/15/2000EP0984936A1 Cyanoguanidines as cell proliferation inhibitors
03/15/2000EP0984934A1 Novel orally active iron (iii) chelators
03/15/2000EP0984930A1 2-indolinone derivatives as modulators of protein kinase activity
03/15/2000EP0984915A2 Lutein esters having high bioavailability
03/15/2000EP0984789A2 Accelerating animal hoof growth with somatotropin
03/15/2000EP0984787A1 Use of low-molecular-weight heparins for preventing and treating cerebral edemas
03/15/2000EP0984780A1 Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome and gestational diabetes
03/15/2000EP0984779A1 Somatostatin agonists
03/15/2000EP0984778A1 Neuropeptide-y ligands
03/15/2000EP0984771A1 Stabilized gas-supersaturated emulsions and suspensions
03/15/2000EP0984699A1 Method of inhibiting immune system destruction of transplanted viable cells
03/15/2000EP0984692A1 Novel angiogenesis inhibitors
03/15/2000EP0619805B1 5-(hetero- or carbocyclylamino)-indole derivatives, their preparation and their use as 5-ht1 agonists
03/15/2000EP0567566B1 Methods for treating tumor necrosis factor mediated diseases
03/15/2000EP0549702B1 Use of recombinant colony stimulating factor-1
03/15/2000CN1247542A Serine protease inhibitors
03/15/2000CN1247539A Process for preparing eprosartan
03/15/2000CN1247538A Process for preparing eprosartan
03/15/2000CN1247191A Imidazolium compound as synthetic material of imidazole lipoxidase inhibitor
03/15/2000CN1247088A Medicinal tea for invigorating function of kidnay and replenishing vital essence
03/15/2000CN1247084A Chinese medicine for treating diseases caused by fatigue
03/15/2000CN1050365C Method for prepn. of hexan-2-olefin pyranoseoside of alcohol and phenol
03/14/2000US6037472 For treating disease-states characterized by excessive activity of matrix metalloproteases such as rheumatoid arthritis, osteoarthritis, periodontal disease, aberrant angiogenesis, tumor invasion and metastasis
03/14/2000US6037470 Purine compounds having PDE IV inhibitory activity and methods of synthesis
03/14/2000US6037469 Beta lactamase inhibitor and antibacterial; for treating bacterial infections in humans and animals
03/14/2000US6037467 Methods for preparing carbohydrate-containing hydrophilic polymers
03/14/2000US6037461 FADD-like anti-apoptotic molecules, methods of using the same, and compositions for and methods of making the same
03/14/2000US6037376 Methods for therapy of cancer
03/14/2000US6037373 Treating nervous system, cytological, hormonal, gastrointestinal and liver disorders
03/14/2000US6037372 Anticarcinogenic agents, viricides
03/14/2000US6037362 Carbazole derivatives; deprotecting, amination; antilipemic and antidiabetic agents; b-adrenaline receptor agonists; dietetics
03/14/2000US6037356 Anticoagulants; antiinflammatory and antiarthritic agents
03/14/2000US6037355 Imidazole lipoxygenase inhibitors
03/14/2000US6037353 Administering terfenadine acid derivative; cardiac side effect reduction
03/14/2000US6037350 Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quionlinone derivatives
03/14/2000US6037347 Comprising a compound which has an acetylcholinesterase-inhibitory action or exhibits muscarinergic action and a compound which increases the endogenous extracellular adenosine level
03/14/2000US6037342 Serotonin 5-HT3 receptor partial activator
03/14/2000US6037327 Specific saccharide compositions and methods for treating Alzheimer's disease and other amyloidoses
03/14/2000US6037325 Certain substituted oxadiazole, thiadiazole and triazole peptoids used effectively to prevent, alleviate or otherwise treat disease states characterized by the degradation of connective tissue such as respiratory system disorders and
03/14/2000US6037324 Madcam-1 (mucosal addressin cell adhesion molecule-1); useful in the treatment of inflammatory bowel diseases and other diseases involving leukocyte infiltration of the gastrointestinal tract or other mucosal tissues
03/14/2000US6037323 Peptides and peptide analogues that mimic the structural and pharmacological properties of human apoa-i; treating disorders associated with dyslipoproteinemia, including hypercholesterolemia, cardiovascular disease, atherosclerosis,
03/14/2000US6037322 Beneficial in preventing the local extension of the microvascular and macrovascular occluding arterial thrombus, thereby reducing the neurological deficit resulting from the stroke; administered by continuous infusion
03/14/2000US6037143 Genetically engineered protein for the treament of diabetes, osteoporosis and endometriosis
03/14/2000US6036956 Method and dosage form using an antagonist to gamma interferon to control MHC-associated autoimmune disease
03/14/2000US6036954 Polypeptides with sequence
03/14/2000US6036126 Apparatus for separating particles of cohesive material according to size and process
03/14/2000CA2125895C Heteroatom-bearing ligands and metal complexes thereof
03/14/2000CA2117643C Indole derivatives
03/14/2000CA2008263C Pyrazolopyridine compound and processes for preparation thereof
03/09/2000WO2000012741A2 Inducible expression system
03/09/2000WO2000012740A2 ADENOVIRUSES DELETED IN THE IVa2, 100K AND/OR PRETERMINAL PROTEIN SEQUENCES
03/09/2000WO2000012726A2 Rationally designed heparinases derived from heparinase i and ii
03/09/2000WO2000012710A1 Nucleic acids encoding ataxin-2 binding proteins, products related thereto and methods of using same
03/09/2000WO2000012683A2 Stem cells bearing an fgf receptor on the cell surface
03/09/2000WO2000012553A1 Cyclic prosaposin-derived peptides and uses thereof
03/09/2000WO2000012551A1 HUMAN LATENT TRANSFORMING GROWTH FACTOR-β BINDING PROTEIN 3
03/09/2000WO2000012549A1 Protein domains in the hepatic glycogen-targetting subunit of protein phosphatase 1 and methods of making and using the same
03/09/2000WO2000012525A1 Sequences characteristic of hypoxia-regulated gene transcription
03/09/2000WO2000012514A1 Novel compounds
03/09/2000WO2000012510A1 Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists
03/09/2000WO2000012509A2 Collections of compounds
03/09/2000WO2000012507A2 Pyrrolobenzodiazepines
03/09/2000WO2000012502A1 Pyrroloquinolines for treatment of obesity
03/09/2000WO2000012501A1 Benzonaphthyridine-n-oxides comprising a pde3 and pde4 inhibiting activity
03/09/2000WO2000012499A1 Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
03/09/2000WO2000012498A1 Quinolin-2-one derivatives useful as anticancer agents
03/09/2000WO2000012497A2 Quinazoline derivatives as medicaments
03/09/2000WO2000012496A1 Novel cdk inhibitors having flavone structure
03/09/2000WO2000012489A1 1, 2, 4-triazole-3-thione compounds
03/09/2000WO2000012485A1 Pyrimidine compounds
03/09/2000WO2000012481A2 Indazole derivatives with 5-ht2 receptor activity________________
03/09/2000WO2000012479A1 2-oxo-2h-quinoline derivatives
03/09/2000WO2000012478A1 Arylpiperazines and their use as metalloproteinase inhibiting agents (mmp)
03/09/2000WO2000012477A1 Hydroxamic acid derivatives as proteinase inhibitors
03/09/2000WO2000012467A1 N-hydroxyacylamino compounds, process for their preparation and pharmaceutical compositions containing them
03/09/2000WO2000012462A1 Aminoalcohol derivatives and their use as beta 3 adrenergic agonists
03/09/2000WO2000012139A1 Hypoxia regulated genes
03/09/2000WO2000012119A2 PHARMACEUTICAL COMPOSITIONS COMPRISING FACTOR XIIIa
03/09/2000WO2000012111A2 Selective treatment of endothelial somatostatin receptors
03/09/2000WO2000012099A1 Promoters of neural regeneration
03/09/2000WO2000012089A1 Novel angiogenesis inhibitors
03/09/2000WO2000012086A1 Method of mitigating the adverse effects of interleukin-2
03/09/2000WO2000012084A1 Geometrically restricted 2-indolinone derivatives as modulators of protein kinase activity
03/09/2000WO2000012083A1 Formamides as therapeutic agents
03/09/2000WO2000012078A1 Therapies for treating pulmonary diseases
1 ... 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 ... 1564